Healthcare Technology Report September 11, 2024

Merck, known as MSD outside the US and Canada, has announced a definitive agreement to acquire CN201, a promising bispecific antibody developed by Curon Biopharmaceutical. This transaction, valued at $700 million upfront, includes potential milestone payments up to $600 million. CN201, currently in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Bridging the Gap: Pharmacists' Role in Advancing Pharmacogenomic Testing Standards

Share This Article